Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 10/20 | 1.00 |
| ▸ | KLK14 | Q9P0G3 | 9/20 | 1.00 |
| ▸ | KLK5 | Q9Y337 | 9/20 | 1.00 |
| ▸ | CTSG | P08311 | 8/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.91 |
| ▸ | CTRC | Q99895 | 3/20 | 0.70 |
| ▸ | C1R | P00736 | 4/20 | 0.60 |
| ▸ | ELANE | P08246 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18352966 | 0.95 | KLK7 (1.00) | KLK7KLK14KLK5CTSGPRSS1 | |
| SCHEMBL18352858 | 0.82 | KLK7 (1.00) | KLK7KLK14KLK5CTSGPRSS1 | |
| SCHEMBL18353555 | 0.82 | KLK7 (1.00) | KLK7KLK14KLK5CTSGPRSS1 | |
| SCHEMBL18353430 | 0.81 | KLK7 (1.00) | KLK7KLK14KLK5CTSGPRSS1 | |
| SCHEMBL18352894 | 0.77 | KLK7 (1.00) | KLK7KLK14KLK5CTSGPRSS1 | |
| SCHEMBL23187443 | 0.77 | KLK7 (0.68) | KLK7KLK14KLK5CTSGPRSS1 | |
| SCHEMBL9984778 | 0.77 | APEX1 (0.76) | KLK7KLK14KLK5CTSGPRSS1 | |
| SCHEMBL18352896 | 0.76 | KLK7 (1.00) | KLK7KLK14KLK5CTSGPRSS1 | |
| SCHEMBL5780185 | 0.76 | C1R (1.00) | KLK7KLK14KLK5CTSGPRSS1 | |
| SCHEMBL912875 | 0.75 | KLK7 (0.85) | KLK7KLK14KLK5CTSGPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3097085-B1 | BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES | SIXERA PHARMA AB (SE) | 2020-07-29 | — | — | EP | disclosed |
| US-20170267692-A1 | BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES | SIXERA PHARMA AB (SE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267692-A1 | BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES | SIXERA PHARMA AB (SE) | 2017-09-21 | — | — | US | disclosed |
| US-9695194-B2 | Benzoxazinone derivatives for treatment of skin diseases | SIXERA PHARMA AB (SE) | 2017-07-04 | — | — | US | disclosed |
| US-9695194-B2 | Benzoxazinone derivatives for treatment of skin diseases | SIXERA PHARMA AB (SE) | 2017-07-04 | — | — | US | disclosed |
| US-20170002021-A1 | BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES | SIXERA PHARMA AB (SE) | 2017-01-05 | — | — | US | disclosed |
| US-20170002021-A1 | BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES | SIXERA PHARMA AB (SE) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267692-A1 | BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES | KLK5, KLK14, KLK7 | KLK7 3/4885KLK14 2/4885KLK5 1/4885 |
| US-20170002021-A1 | BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES | KLK5, KLK14, KLK7 | KLK7 3/4885KLK14 2/4885KLK5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.